ORIC Pharmaceuticals (ORIC) News Today $9.59 +0.47 (+5.15%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cantor Fitzgerald Issues Negative Forecast for ORIC EarningsNovember 20 at 1:53 AM | americanbankingnews.comFirst Turn Management LLC Sells 64,923 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)First Turn Management LLC lessened its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,451,037 shares ofNovember 19, 2024 | marketbeat.comResearch Analysts Issue Forecasts for ORIC FY2024 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst P. Agrawal now anticipates tNovember 18, 2024 | marketbeat.comFY2024 EPS Estimate for ORIC Pharmaceuticals Cut by AnalystORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Wedbush decreased their FY2024 EPS estimates for ORIC Pharmaceuticals in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.82) per shNovember 15, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from WedbushNovember 14, 2024 | americanbankingnews.comOric Pharmaceuticals Reports Strong Financial Growth and Clinical ProgressNovember 14, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)November 13, 2024 | markets.businessinsider.comORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesNovember 13, 2024 | markets.businessinsider.comPositive Outlook on ORIC-114: Promising Preclinical Results and Selective Efficacy Bolster Buy RatingNovember 5, 2024 | markets.businessinsider.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2% - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 5.2% - Time to Sell?November 4, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a report on Monday.November 4, 2024 | marketbeat.comWells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight RecommendationNovember 1, 2024 | msn.comORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comJones Trading Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy RecommendationNovember 1, 2024 | msn.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Should You Buy?October 31, 2024 | marketbeat.comOric Pharmaceuticals initiated with a Buy at JonesResearchOctober 31, 2024 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Wells Fargo & CompanyWells Fargo & Company initiated coverage on ORIC Pharmaceuticals in a research note on Thursday. They set an "overweight" rating and a $20.00 price objective for the company.October 31, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 8.4% - Should You Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 8.4% Higher - Should You Buy?October 29, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Buy" from BrokeragesShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average twelvOctober 29, 2024 | marketbeat.comOric Pharmaceuticals presents data on ORIC-114October 24, 2024 | markets.businessinsider.comCandid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of DirectorsOctober 17, 2024 | finance.yahoo.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 4.5% Higher - Still a Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 4.5% Higher - Here's What HappenedOctober 14, 2024 | marketbeat.comSG Americas Securities LLC Takes $714,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)SG Americas Securities LLC bought a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 69,620 shares of the company's stock, valueOctober 14, 2024 | marketbeat.comMillennium Management LLC Boosts Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Millennium Management LLC grew its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 297.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 782,299 shares of the company's stock afOctober 12, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by Dimensional Fund Advisors LPDimensional Fund Advisors LP lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 190.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 466,662 shares of the company's stock after buying an aOctober 11, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 9, 2024 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 4.2% - Here's WhyORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 4.2% - Here's WhyOctober 8, 2024 | marketbeat.comWedbush Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)October 7, 2024 | markets.businessinsider.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | globenewswire.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Buy" by BrokeragesORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month priceOctober 4, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 4.3%ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 4.3%October 2, 2024 | marketbeat.comFred Alger Management LLC Trims Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Fred Alger Management LLC cut its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 29.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,912 shares of the company's stock aftSeptember 28, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)September 27, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on AnaptysBio (ANAB)September 27, 2024 | markets.businessinsider.comBrokers Set Expectations for ORIC Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for shares of ORIC Pharmaceuticals in a report released on Monday, September 23rd. Cantor Fitzgerald analyst P. Agrawal now expects that the company will earnSeptember 25, 2024 | marketbeat.comBank of New York Mellon Corp Has $1.32 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Bank of New York Mellon Corp boosted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 62.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,484 shares of the company's stSeptember 20, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% Higher ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 11.6%September 19, 2024 | marketbeat.comBuy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical AdvancesSeptember 18, 2024 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Wednesday.September 18, 2024 | marketbeat.comOpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery CollaborationSeptember 18, 2024 | finance.yahoo.comTD Asset Management Inc Decreases Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)TD Asset Management Inc lessened its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 33.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,400 shares of the company's stock after sellingSeptember 15, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 11.7% Higher ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 11.7% HigherSeptember 13, 2024 | marketbeat.comFirst Turn Management LLC Buys 418,389 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)First Turn Management LLC boosted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 38.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,515,960 shares of the compaSeptember 13, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.7% ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.7%September 12, 2024 | marketbeat.comOric Pharmaceuticals (ORIC) Gets a Buy from WedbushSeptember 11, 2024 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Rating Reaffirmed by WedbushWedbush reaffirmed an "outperform" rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Tuesday.September 10, 2024 | marketbeat.comMonaco Asset Management SAM Purchases 171,650 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Monaco Asset Management SAM raised its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 132.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 301,650 shares of the company'sSeptember 10, 2024 | marketbeat.comWedbush Sticks to Its Buy Rating for Nuvalent (NUVL)September 9, 2024 | markets.businessinsider.com Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump Wins… But Elon Says Get Ready to Brace (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼-0.350.49▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼83▲ORIC Articles Average Week Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phathom Pharmaceuticals News Today Innate Pharma News Today Karyopharm Therapeutics News Today Arcutis Biotherapeutics News Today BioXcel Therapeutics News Today Supernus Pharmaceuticals News Today Zai Lab News Today Catalyst Pharmaceuticals News Today Iovance Biotherapeutics News Today Scholar Rock News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORIC Stock Alerts